Bariatric surgery: a systematic review and meta-analysis.

The Look AHEAD study: a description of the lifestyle intervention and the evidence supporting it. Obesity (Silver Spring) (2006) 8.25

Human gut microbiota in obesity and after gastric bypass. Proc Natl Acad Sci U S A (2009) 8.25

Perioperative safety in the longitudinal assessment of bariatric surgery. N Engl J Med (2009) 8.06

Metabolic mediators of the effects of body-mass index, overweight, and obesity on coronary heart disease and stroke: a pooled analysis of 97 prospective cohorts with 1·8 million participants. Lancet (2013) 7.34

The metabolic syndrome. Endocr Rev (2008) 5.33

Effect of weight loss by gastric bypass surgery versus hypocaloric diet on glucose and incretin levels in patients with type 2 diabetes. J Clin Endocrinol Metab (2008) 4.19

Incretin levels and effect are markedly enhanced 1 month after Roux-en-Y gastric bypass surgery in obese patients with type 2 diabetes. Diabetes Care (2007) 3.97

The mechanism of diabetes control after gastrointestinal bypass surgery reveals a role of the proximal small intestine in the pathophysiology of type 2 diabetes. Ann Surg (2006) 3.97

Safety and efficacy of bariatric surgery: Longitudinal Assessment of Bariatric Surgery. Surg Obes Relat Dis (2007) 3.67

Weight change and health outcomes at 3 years after bariatric surgery among individuals with severe obesity. JAMA (2013) 3.57

Differential adaptation of human gut microbiota to bariatric surgery-induced weight loss: links with metabolic and low-grade inflammation markers. Diabetes (2010) 3.39

Reprogramming of intestinal glucose metabolism and glycemic control in rats after gastric bypass. Science (2013) 3.26

Bariatric surgery for obesity and metabolic conditions in adults. BMJ (2014) 3.22

Differential metabolic impact of gastric bypass surgery versus dietary intervention in obese diabetic subjects despite identical weight loss. Sci Transl Med (2011) 3.20

Serum bile acids are higher in humans with prior gastric bypass: potential contribution to improved glucose and lipid metabolism. Obesity (Silver Spring) (2009) 3.15

Association of adolescent obesity with risk of severe obesity in adulthood. JAMA (2010) 3.10

A multisite study of long-term remission and relapse of type 2 diabetes mellitus following gastric bypass. Obes Surg (2013) 3.06

Exaggerated glucagon-like peptide-1 and blunted glucose-dependent insulinotropic peptide secretion are associated with Roux-en-Y gastric bypass but not adjustable gastric banding. Surg Obes Relat Dis (2007) 3.01

A survey of the genetics of stomach, liver, and adipose gene expression from a morbidly obese cohort. Genome Res (2011) 3.00

The effectiveness and risks of bariatric surgery: an updated systematic review and meta-analysis, 2003-2012. JAMA Surg (2014) 2.91

Treatment of obesity in primary care practice in the United States: a systematic review. J Gen Intern Med (2009) 2.89

Bariatric surgery: an IDF statement for obese Type 2 diabetes. Diabet Med (2011) 2.74

Acute effects of gastric bypass versus gastric restrictive surgery on beta-cell function and insulinotropic hormones in severely obese patients with type 2 diabetes. Int J Obes (Lond) (2009) 2.70

Obesity and obstructive sleep apnea: pathogenic mechanisms and therapeutic approaches. Proc Am Thorac Soc (2008) 2.49

Fibrosis in human adipose tissue: composition, distribution, and link with lipid metabolism and fat mass loss. Diabetes (2010) 2.46

Prospective study of gut hormone and metabolic changes after adjustable gastric banding and Roux-en-Y gastric bypass. Int J Obes (Lond) (2009) 2.28

Prevalence of Helicobacter pylori seropositivity among patients undergoing bariatric surgery: a preliminary study. World J Surg (2008) 2.22

Beyond BMI: the need for new guidelines governing the use of bariatric and metabolic surgery. Lancet Diabetes Endocrinol (2014) 2.16

Predictive value of upper gastrointestinal studies versus clinical signs for gastrointestinal leaks after laparoscopic gastric bypass. Surg Endosc (2006) 2.14

Controlled-release phentermine/topiramate in severely obese adults: a randomized controlled trial (EQUIP). Obesity (Silver Spring) (2011) 2.09

Effects of gastric bypass surgery in patients with type 2 diabetes and only mild obesity. Diabetes Care (2012) 2.08

Fibrosis and adipose tissue dysfunction. Cell Metab (2013) 2.07

The impact of psychological support on weight loss post weight loss surgery: a randomised control trial. Obes Surg (2015) 2.04

Roux-en-Y gastric bypass enhances energy expenditure and extends lifespan in diet-induced obese rats. Obesity (Silver Spring) (2009) 2.04

Metabolic surgery for type 2 diabetes with BMI <35 kg/m(2) : an endocrinologist's perspective. Obes Surg (2013) 2.00

Health and functioning among baby boomers approaching 60. J Gerontol B Psychol Sci Soc Sci (2009) 1.98

Referring survivors of endometrial cancer and complex atypical hyperplasia to bariatric specialists: a prospective cohort study. Am J Obstet Gynecol (2015) 1.97

Ileal interposition surgery improves glucose and lipid metabolism and delays diabetes onset in the UCD-T2DM rat. Gastroenterology (2010) 1.96

The age-specific quantitative effects of metabolic risk factors on cardiovascular diseases and diabetes: a pooled analysis. PLoS One (2013) 1.95

Epidemiology of Obstructive Sleep Apnea: a Population-based Perspective. Expert Rev Respir Med (2008) 1.94

Contribution of endogenous glucagon-like peptide 1 to glucose metabolism after Roux-en-Y gastric bypass. Diabetes (2013) 1.90

Diabetes remission and reduced cardiovascular risk after gastric bypass in Asian Indians with body mass index <35 kg/m(2). Surg Obes Relat Dis (2009) 1.88

Weight loss interventions in chronic kidney disease: a systematic review and meta-analysis. Clin J Am Soc Nephrol (2009) 1.86

Involvement of gut microbiota in the development of low-grade inflammation and type 2 diabetes associated with obesity. Gut Microbes (2012) 1.83

Bands and bypasses: 30-day morbidity and mortality of bariatric surgical procedures as assessed by prospective, multi-center, risk-adjusted ACS-NSQIP data. Surg Endosc (2008) 1.82

Risk of suicide after long-term follow-up from bariatric surgery. Am J Med (2010) 1.81

Interactions between obesity and obstructive sleep apnea: implications for treatment. Chest (2010) 1.79

Perinatal outcomes after bariatric surgery: nationwide population based matched cohort study. BMJ (2013) 1.79

Duodenal switch provides superior weight loss in the super-obese (BMI > or =50 kg/m2) compared with gastric bypass. Ann Surg (2006) 1.78

Bariatric surgery among kidney transplant candidates and recipients: analysis of the United States renal data system and literature review. Transplantation (2009) 1.75

Retracted Transformation of postingestive glucose responses after deletion of sweet taste receptor subunits or gastric bypass surgery. Am J Physiol Endocrinol Metab (2012) 1.74

All bariatric surgeries are not created equal: insights from mechanistic comparisons. Endocr Rev (2012) 1.74

Oxalate nephropathy complicating Roux-en-Y Gastric Bypass: an underrecognized cause of irreversible renal failure. Clin J Am Soc Nephrol (2008) 1.72

Best practice updates for pediatric/adolescent weight loss surgery. Obesity (Silver Spring) (2009) 1.71

Heritability of the weight loss response to gastric bypass surgery. J Clin Endocrinol Metab (2011) 1.71

Metabolic and hormonal changes after laparoscopic Roux-en-Y gastric bypass and sleeve gastrectomy: a randomized, prospective trial. Obes Surg (2012) 1.71

Long-term effects of laparoscopic sleeve gastrectomy, gastric bypass, and adjustable gastric banding on type 2 diabetes. Surg Endosc (2009) 1.69

Bariatric surgery reduces visceral adipose inflammation and improves endothelial function in type 2 diabetic mice. Arterioscler Thromb Vasc Biol (2011) 1.69

Optimizing long-term weight control after bariatric surgery: a pilot study. Surg Obes Relat Dis (2011) 1.68

Sleeve gastrectomy in rats improves postprandial lipid clearance by reducing intestinal triglyceride secretion. Gastroenterology (2011) 1.64

Bariatric surgery: risks and rewards. J Clin Endocrinol Metab (2008) 1.63

Effects of gastric bypass surgery on female reproductive function. J Clin Endocrinol Metab (2012) 1.63

The use, safety and cost of bariatric surgery before and after Medicare's national coverage decision. Ann Surg (2011) 1.63

Mechanism for improved insulin sensitivity after gastric bypass surgery. J Clin Endocrinol Metab (2008) 1.62

Improved memory function 12 weeks after bariatric surgery. Surg Obes Relat Dis (2010) 1.62

Teen-Longitudinal Assessment of Bariatric Surgery: methodological features of the first prospective multicenter study of adolescent bariatric surgery. J Pediatr Surg (2007) 1.61

Gastrojejunal stoma diameter predicts weight regain after Roux-en-Y gastric bypass. Clin Gastroenterol Hepatol (2010) 1.60

Trends in health of older adults in the United States: past, present, future. Demography (2010) 1.60

Improvement in peripheral glucose uptake after gastric bypass surgery is observed only after substantial weight loss has occurred and correlates with the magnitude of weight lost. J Gastrointest Surg (2009) 1.56

Preoperative eating behavior, postoperative dietary adherence, and weight loss after gastric bypass surgery. Surg Obes Relat Dis (2008) 1.56

Deterioration of mental health in bariatric surgery after 10 years despite successful weight loss. Eur J Clin Nutr (2015) 1.56

Kidney stone incidence and metabolic urinary changes after modern bariatric surgery: review of clinical studies, experimental models, and prevention strategies. Surg Obes Relat Dis (2014) 1.56

Bariatric surgery for type 2 diabetes: weighing the impact for obese patients. Cleve Clin J Med (2010) 1.54

Intestinal adaptation after ileal interposition surgery increases bile acid recycling and protects against obesity-related comorbidities. Am J Physiol Gastrointest Liver Physiol (2010) 1.54

Body mass index and outcome in renal transplant recipients: a systematic review and meta-analysis. BMC Med (2015) 1.52

Thirty-day morbidity and mortality of the laparoscopic ileal interposition associated with sleeve gastrectomy for the treatment of type 2 diabetic patients with BMI <35: an analysis of 454 consecutive patients. World J Surg (2011) 1.52

The gut microbiota and its relationship to diet and obesity: new insights. Gut Microbes (2012) 1.52

Effects of 7 days of exercise training on insulin sensitivity and responsiveness in type 2 diabetes mellitus. Am J Physiol Endocrinol Metab (2009) 1.50

Impact of bariatric surgery on health care utilization and costs among patients with diabetes. Med Care (2012) 1.49

Loss of control over eating predicts outcomes in bariatric surgery patients: a prospective, 24-month follow-up study. J Clin Psychiatry (2009) 1.49

Thermogenic changes after gastric bypass, adjustable gastric banding or diet alone. Surgery (2014) 1.48

Bariatric surgery and diabetes: who should be offered the option of remission? JAMA (2009) 1.48

Relative contributions of afferent vagal fibers to resistance to diet-induced obesity. Dig Dis Sci (2011) 1.48

Early results of the Swiss Multicentre Bypass or Sleeve Study (SM-BOSS): a prospective randomized trial comparing laparoscopic sleeve gastrectomy and Roux-en-Y gastric bypass. Ann Surg (2013) 1.47

Effect of preoperative body mass index on weight loss after obesity surgery. Surg Obes Relat Dis (2013) 1.47

Clinical review: Regulation of food intake, energy balance, and body fat mass: implications for the pathogenesis and treatment of obesity. J Clin Endocrinol Metab (2012) 1.47

Selective reduction in neural responses to high calorie foods following gastric bypass surgery. Ann Surg (2011) 1.46

Gut feelings about diabetes. Endocrinol Nutr (2012) 1.46

Weight loss and incretin responsiveness improve glucose control independently after gastric bypass surgery. J Diabetes (2010) 1.46

Melanocortin-4 receptor signaling is required for weight loss after gastric bypass surgery. J Clin Endocrinol Metab (2012) 1.46

Bariatric surgery: a systematic review of the clinical and economic evidence. J Gen Intern Med (2011) 1.45

Do Incretins play a role in the remission of type 2 diabetes after gastric bypass surgery: What are the evidence? Obes Surg (2008) 1.45

SLEEVEPASS: a randomized prospective multicenter study comparing laparoscopic sleeve gastrectomy and gastric bypass in the treatment of morbid obesity: preliminary results. Surg Endosc (2012) 1.44

Female Sexual Function Before and After Bariatric Surgery: a Cross-Sectional Study and Review of Literature. Obes Surg (2015) 1.44

Prospective randomized clinical trial of laparoscopic sleeve gastrectomy versus open Roux-en-Y gastric bypass for the management of patients with morbid obesity. Wideochir Inne Tech Maloinwazyjne (2012) 1.42

Laboratory testing for and diagnosis of nutritional deficiencies in pregnancy before and after bariatric surgery. J Womens Health (Larchmt) (2013) 1.42

Predictors of success after laparoscopic gastric bypass: a multivariate analysis of socioeconomic factors. Surg Endosc (2006) 1.42

Relationship of body mass index with demographic and clinical characteristics in the Longitudinal Assessment of Bariatric Surgery (LABS). Surg Obes Relat Dis (2008) 1.41

Impact of different bariatric surgical procedures on insulin action and beta-cell function in type 2 diabetes. Diabetes Care (2009) 1.41

The Mini-Mental State Exam (MMSE) is not sensitive to cognitive impairment in bariatric surgery candidates. Surg Obes Relat Dis (2013) 1.40

Intensive versus moderate lipid lowering with statins after acute coronary syndromes. N Engl J Med (2004) 19.42

Prasugrel versus clopidogrel in patients with acute coronary syndromes. N Engl J Med (2007) 17.85

Weight and type 2 diabetes after bariatric surgery: systematic review and meta-analysis. Am J Med (2009) 13.91

Ezetimibe Added to Statin Therapy after Acute Coronary Syndromes. N Engl J Med (2015) 13.90

Diuretic strategies in patients with acute decompensated heart failure. N Engl J Med (2011) 11.99

Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus. N Engl J Med (2013) 11.34

Twelve or 30 months of dual antiplatelet therapy after drug-eluting stents. N Engl J Med (2014) 10.54

Early intensive vs a delayed conservative simvastatin strategy in patients with acute coronary syndromes: phase Z of the A to Z trial. JAMA (2004) 9.74

C-reactive protein levels and outcomes after statin therapy. N Engl J Med (2005) 9.47

Cytochrome p-450 polymorphisms and response to clopidogrel. N Engl J Med (2008) 9.25

Long-term use of ticagrelor in patients with prior myocardial infarction. N Engl J Med (2015) 8.69

Ultrafiltration in decompensated heart failure with cardiorenal syndrome. N Engl J Med (2012) 8.28

Risk of incident diabetes with intensive-dose compared with moderate-dose statin therapy: a meta-analysis. JAMA (2011) 8.24

Perioperative safety in the longitudinal assessment of bariatric surgery. N Engl J Med (2009) 8.06

DHEA in elderly women and DHEA or testosterone in elderly men. N Engl J Med (2006) 7.90

Edoxaban versus warfarin in patients with atrial fibrillation. N Engl J Med (2013) 7.70

Rivaroxaban in patients with a recent acute coronary syndrome. N Engl J Med (2011) 7.30

Routine vs selective invasive strategies in patients with acute coronary syndromes: a collaborative meta-analysis of randomized trials. JAMA (2005) 6.81

Efficacy and tolerability of rimonabant in overweight or obese patients with type 2 diabetes: a randomised controlled study. Lancet (2006) 6.50

Interindividual variation in posture allocation: possible role in human obesity. Science (2005) 6.26

Prasugrel compared with clopidogrel in patients undergoing percutaneous coronary intervention for ST-elevation myocardial infarction (TRITON-TIMI 38): double-blind, randomised controlled trial. Lancet (2009) 6.19

A sensitive cardiac troponin T assay in stable coronary artery disease. N Engl J Med (2009) 5.81

Addition of clopidogrel to aspirin and fibrinolytic therapy for myocardial infarction with ST-segment elevation. N Engl J Med (2005) 5.28

2013 AHA/ACC/TOS guideline for the management of overweight and obesity in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and The Obesity Society. J Am Coll Cardiol (2013) 5.24

2013 AHA/ACC/TOS guideline for the management of overweight and obesity in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and The Obesity Society. Circulation (2013) 5.02

Effect of phosphodiesterase-5 inhibition on exercise capacity and clinical status in heart failure with preserved ejection fraction: a randomized clinical trial. JAMA (2013) 4.85

Intensive oral antiplatelet therapy for reduction of ischaemic events including stent thrombosis in patients with acute coronary syndromes treated with percutaneous coronary intervention and stenting in the TRITON-TIMI 38 trial: a subanalysis of a randomised trial. Lancet (2008) 4.71

ACC/AHA 2002 guideline update for the management of patients with unstable angina and non-ST-segment elevation myocardial infarction--summary article: a report of the American College of Cardiology/American Heart Association task force on practice guidelines (Committee on the Management of Patients With Unstable Angina). J Am Coll Cardiol (2002) 4.64

A tale of coronary artery disease and myocardial infarction. N Engl J Med (2012) 4.53

Isosorbide Mononitrate in Heart Failure with Preserved Ejection Fraction. N Engl J Med (2015) 4.39

Pharmacodynamic effect and clinical efficacy of clopidogrel and prasugrel with or without a proton-pump inhibitor: an analysis of two randomised trials. Lancet (2009) 4.31

Meta-analysis of cardiovascular outcomes trials comparing intensive versus moderate statin therapy. J Am Coll Cardiol (2006) 4.16

Antibiotic treatment of Chlamydia pneumoniae after acute coronary syndrome. N Engl J Med (2005) 4.13

Vorapaxar in the secondary prevention of atherothrombotic events. N Engl J Med (2012) 4.10

Splanchnic lipolysis in human obesity. J Clin Invest (2004) 3.94

Obstructive sleep apnea and risk of motor vehicle crash: systematic review and meta-analysis. J Clin Sleep Med (2009) 3.84

ACC/AHA guideline update for the management of patients with unstable angina and non-ST-segment elevation myocardial infarction--2002: summary article: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on the Management of Patients With Unstable Angina). Circulation (2002) 3.80

Efficacy and safety of LDL-lowering therapy among men and women: meta-analysis of individual data from 174,000 participants in 27 randomised trials. Lancet (2015) 3.79

The effect of routine, early invasive management on outcome for elderly patients with non-ST-segment elevation acute coronary syndromes. Ann Intern Med (2004) 3.78

Enoxaparin versus unfractionated heparin with fibrinolysis for ST-elevation myocardial infarction. N Engl J Med (2006) 3.56

Roux-en-Y gastric bypass vs intensive medical management for the control of type 2 diabetes, hypertension, and hyperlipidemia: the Diabetes Surgery Study randomized clinical trial. JAMA (2013) 3.49

State of the art: using natriuretic peptide levels in clinical practice. Eur J Heart Fail (2008) 3.35

Fat tissue, aging, and cellular senescence. Aging Cell (2010) 3.34

Greater clinical benefit of more intensive oral antiplatelet therapy with prasugrel in patients with diabetes mellitus in the trial to assess improvement in therapeutic outcomes by optimizing platelet inhibition with prasugrel-Thrombolysis in Myocardial Infarction 38. Circulation (2008) 3.25

Prognostic implications of elevated troponin in patients with suspected acute coronary syndrome but no critical epicardial coronary disease: a TACTICS-TIMI-18 substudy. J Am Coll Cardiol (2005) 3.20

Early invasive vs conservative treatment strategies in women and men with unstable angina and non-ST-segment elevation myocardial infarction: a meta-analysis. JAMA (2008) 3.12

Identification of depot-specific human fat cell progenitors through distinct expression profiles and developmental gene patterns. Am J Physiol Endocrinol Metab (2006) 3.03

Rationale and design of IMPROVE-IT (IMProved Reduction of Outcomes: Vytorin Efficacy International Trial): comparison of ezetimbe/simvastatin versus simvastatin monotherapy on cardiovascular outcomes in patients with acute coronary syndromes. Am Heart J (2008) 3.02

Effect of clopidogrel pretreatment before percutaneous coronary intervention in patients with ST-elevation myocardial infarction treated with fibrinolytics: the PCI-CLARITY study. JAMA (2005) 2.93

Detection of acute changes in circulating troponin in the setting of transient stress test-induced myocardial ischaemia using an ultrasensitive assay: results from TIMI 35. Eur Heart J (2008) 2.92

Multimarker approach to risk stratification in non-ST elevation acute coronary syndromes: simultaneous assessment of troponin I, C-reactive protein, and B-type natriuretic peptide. Circulation (2002) 2.86

Proteinuria, impaired kidney function, and adverse outcomes in people with coronary disease: analysis of a previously conducted randomised trial. BMJ (2006) 2.85

The 50-year history, controversy, and clinical implications of left ventricular outflow tract obstruction in hypertrophic cardiomyopathy from idiopathic hypertrophic subaortic stenosis to hypertrophic cardiomyopathy: from idiopathic hypertrophic subaortic stenosis to hypertrophic cardiomyopathy. J Am Coll Cardiol (2009) 2.79

Relationship between nonsustained ventricular tachycardia after non-ST-elevation acute coronary syndrome and sudden cardiac death: observations from the metabolic efficiency with ranolazine for less ischemia in non-ST-elevation acute coronary syndrome-thrombolysis in myocardial infarction 36 (MERLIN-TIMI 36) randomized controlled trial. Circulation (2010) 2.76

Impact of triglyceride levels beyond low-density lipoprotein cholesterol after acute coronary syndrome in the PROVE IT-TIMI 22 trial. J Am Coll Cardiol (2008) 2.75

Benefit of an early invasive management strategy in women with acute coronary syndromes. JAMA (2002) 2.75

Genetic variants in ABCB1 and CYP2C19 and cardiovascular outcomes after treatment with clopidogrel and prasugrel in the TRITON-TIMI 38 trial: a pharmacogenetic analysis. Lancet (2010) 2.72

Normal weight obesity: a risk factor for cardiometabolic dysregulation and cardiovascular mortality. Eur Heart J (2009) 2.71

Association between plasma levels of monocyte chemoattractant protein-1 and long-term clinical outcomes in patients with acute coronary syndromes. Circulation (2003) 2.70

Effect of ranolazine, an antianginal agent with novel electrophysiological properties, on the incidence of arrhythmias in patients with non ST-segment elevation acute coronary syndrome: results from the Metabolic Efficiency With Ranolazine for Less Ischemia in Non ST-Elevation Acute Coronary Syndrome Thrombolysis in Myocardial Infarction 36 (MERLIN-TIMI 36) randomized controlled trial. Circulation (2007) 2.64

Early and late benefits of high-dose atorvastatin in patients with acute coronary syndromes: results from the PROVE IT-TIMI 22 trial. J Am Coll Cardiol (2005) 2.62

Effects of ranolazine on recurrent cardiovascular events in patients with non-ST-elevation acute coronary syndromes: the MERLIN-TIMI 36 randomized trial. JAMA (2007) 2.57

Mechanisms of the age-associated deterioration in glucose tolerance: contribution of alterations in insulin secretion, action, and clearance. Diabetes (2003) 2.53

Early versus delayed, provisional eptifibatide in acute coronary syndromes. N Engl J Med (2009) 2.49

Safety and efficacy of enoxaparin vs unfractionated heparin in patients with non-ST-segment elevation acute coronary syndromes who receive tirofiban and aspirin: a randomized controlled trial. JAMA (2004) 2.46

The natural history and prognosis of neovascular age-related macular degeneration: a systematic review of the literature and meta-analysis. Ophthalmology (2007) 2.46

Prognostic value of B-Type natriuretic peptides in patients with stable coronary artery disease: the PEACE Trial. J Am Coll Cardiol (2007) 2.40

Diagnostic performance of body mass index to detect obesity in patients with coronary artery disease. Eur Heart J (2007) 2.38

Trends in mortality in bariatric surgery: a systematic review and meta-analysis. Surgery (2007) 2.35

Normal-Weight Central Obesity: Implications for Total and Cardiovascular Mortality. Ann Intern Med (2015) 2.31

Meta-analysis of alignment outcomes in computer-assisted total knee arthroplasty surgery. J Arthroplasty (2007) 2.26

Collaborating with industry--choices for the academic medical center. N Engl J Med (2002) 2.24

Association of hemoglobin levels with clinical outcomes in acute coronary syndromes. Circulation (2005) 2.24

Prospective evaluation of the prognostic implications of improved assay performance with a sensitive assay for cardiac troponin I. J Am Coll Cardiol (2010) 2.24

B-type natriuretic peptide and the effect of ranolazine in patients with non-ST-segment elevation acute coronary syndromes: observations from the MERLIN-TIMI 36 (Metabolic Efficiency With Ranolazine for Less Ischemia in Non-ST Elevation Acute Coronary-Thrombolysis In Myocardial Infarction 36) trial. J Am Coll Cardiol (2010) 2.23

Obesity as a disease: a white paper on evidence and arguments commissioned by the Council of the Obesity Society. Obesity (Silver Spring) (2008) 2.23

Fat depot origin affects adipogenesis in primary cultured and cloned human preadipocytes. Am J Physiol Regul Integr Comp Physiol (2002) 2.23

Association of the Trp719Arg polymorphism in kinesin-like protein 6 with myocardial infarction and coronary heart disease in 2 prospective trials: the CARE and WOSCOPS trials. J Am Coll Cardiol (2008) 2.21

Bariatric surgery in class I obesity : a Position Statement from the International Federation for the Surgery of Obesity and Metabolic Disorders (IFSO). Obes Surg (2014) 2.20

Cytochrome P450 genetic polymorphisms and the response to prasugrel: relationship to pharmacokinetic, pharmacodynamic, and clinical outcomes. Circulation (2009) 2.20

Association of creatinine and creatinine clearance on presentation in acute myocardial infarction with subsequent mortality. J Am Coll Cardiol (2003) 2.19

Regional differences in cellular mechanisms of adipose tissue gain with overfeeding. Proc Natl Acad Sci U S A (2010) 2.17

Prognostic value of serial B-type natriuretic peptide testing during follow-up of patients with unstable coronary artery disease. JAMA (2005) 2.17

Abundance of two human preadipocyte subtypes with distinct capacities for replication, adipogenesis, and apoptosis varies among fat depots. Am J Physiol Endocrinol Metab (2004) 2.16

Continuous positive airway pressure reduces risk of motor vehicle crash among drivers with obstructive sleep apnea: systematic review and meta-analysis. Sleep (2010) 2.16

Systematic review and meta-analysis of bariatric surgery for pediatric obesity. Ann Surg (2008) 2.15

Prevalence and clinical outcomes of undiagnosed diabetes mellitus and prediabetes among patients with high-risk non-ST-segment elevation acute coronary syndrome. Am Heart J (2013) 2.14

Prasugrel compared with high loading- and maintenance-dose clopidogrel in patients with planned percutaneous coronary intervention: the Prasugrel in Comparison to Clopidogrel for Inhibition of Platelet Activation and Aggregation-Thrombolysis in Myocardial Infarction 44 trial. Circulation (2007) 2.13

Polymorphism in KIF6 gene and benefit from statins after acute coronary syndromes: results from the PROVE IT-TIMI 22 study. J Am Coll Cardiol (2008) 2.12

Cost-effectiveness of prasugrel versus clopidogrel in patients with acute coronary syndromes and planned percutaneous coronary intervention: results from the trial to assess improvement in therapeutic outcomes by optimizing platelet inhibition with Prasugrel-Thrombolysis in Myocardial Infarction TRITON-TIMI 38. Circulation (2009) 2.09

Effects of digoxin at low serum concentrations on mortality and hospitalization in heart failure: a propensity-matched study of the DIG trial. Int J Cardiol (2007) 2.05

Serial measurement of monocyte chemoattractant protein-1 after acute coronary syndromes: results from the A to Z trial. J Am Coll Cardiol (2007) 2.03

Left ventricular remodeling and ventricular arrhythmias after myocardial infarction. Circulation (2003) 2.03

Pregnancy outcomes in women with epilepsy: a systematic review and meta-analysis of published pregnancy registries and cohorts. Epilepsy Res (2008) 2.02

Renal function and effectiveness of angiotensin-converting enzyme inhibitor therapy in patients with chronic stable coronary disease in the Prevention of Events with ACE inhibition (PEACE) trial. Circulation (2006) 2.01

Loop diuretics in acute decompensated heart failure: necessary? Evil? A necessary evil? Circ Heart Fail (2009) 2.01

Vorapaxar for secondary prevention of thrombotic events for patients with previous myocardial infarction: a prespecified subgroup analysis of the TRA 2°P-TIMI 50 trial. Lancet (2012) 2.00

Differential expression of cardiac biomarkers by gender in patients with unstable angina/non-ST-elevation myocardial infarction: a TACTICS-TIMI 18 (Treat Angina with Aggrastat and determine Cost of Therapy with an Invasive or Conservative Strategy-Thrombolysis In Myocardial Infarction 18) substudy. Circulation (2004) 1.99

Long-term opioid therapy for chronic noncancer pain: a systematic review and meta-analysis of efficacy and safety. J Pain Symptom Manage (2008) 1.99